SYMLIN Drug Patent Profile
✉ Email this page to a colleague
When do Symlin patents expire, and when can generic versions of Symlin launch?
Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA.
The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pramlintide acetate profile page.
Summary for SYMLIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 11 |
Clinical Trials: | 20 |
Patent Applications: | 2,786 |
Drug Prices: | Drug price information for SYMLIN |
DailyMed Link: | SYMLIN at DailyMed |
Recent Clinical Trials for SYMLIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boston University | Early Phase 1 |
National Institute on Aging (NIA) | Early Phase 1 |
H. Lee Moffitt Cancer Center and Research Institute | Early Phase 1 |
Pharmacology for SYMLIN
Drug Class | Amylin Analog |
Mechanism of Action | Amylin Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for SYMLIN
US Patents and Regulatory Information for SYMLIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Ab | SYMLIN | pramlintide acetate | INJECTABLE;SUBCUTANEOUS | 021332-002 | Sep 25, 2007 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astrazeneca Ab | SYMLIN | pramlintide acetate | INJECTABLE;SUBCUTANEOUS | 021332-003 | Sep 25, 2007 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astrazeneca Ab | SYMLIN | pramlintide acetate | INJECTABLE;SUBCUTANEOUS | 021332-001 | Mar 16, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SYMLIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca Ab | SYMLIN | pramlintide acetate | INJECTABLE;SUBCUTANEOUS | 021332-001 | Mar 16, 2005 | ⤷ Try a Trial | ⤷ Try a Trial |
Astrazeneca Ab | SYMLIN | pramlintide acetate | INJECTABLE;SUBCUTANEOUS | 021332-001 | Mar 16, 2005 | ⤷ Try a Trial | ⤷ Try a Trial |
Astrazeneca Ab | SYMLIN | pramlintide acetate | INJECTABLE;SUBCUTANEOUS | 021332-003 | Sep 25, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
Astrazeneca Ab | SYMLIN | pramlintide acetate | INJECTABLE;SUBCUTANEOUS | 021332-002 | Sep 25, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SYMLIN
See the table below for patents covering SYMLIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 0525158 | ⤷ Try a Trial | |
Japan | H05505625 | ⤷ Try a Trial | |
Spain | 2122995 | ⤷ Try a Trial | |
Japan | 2828250 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |